BLS Pharmaceuticals Delivers Record FY26 as International Manufacturing Platform Scales
BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising ...
BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
